Motac
Preclinical CRO
Specialists in preclinical proof of concept and efficacy studies
Our expertise
Advancing CNS Research
As a specialised neuroscience contract research organisation (CRO) focused on CNS therapeutic development, we deliver advanced preclinical services tailored to biotechnology and pharmaceutical companies. We help advance novel therapies for complex neurological and psychiatric disorders, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and other movement and cognitive disorders.
By combining validated translational models with rigorous scientific expertise, we help our clients and partners generate robust preclinical proof-of-concept data, reduce development risk and accelerate their programmes towards clinical development.
Preclinical Experience
Our extensive experience in preclinical neuroscience enables our scientists to provide expert guidance on study design and conduct tailored studies to rigorous scientific standards, following established SOPs and agreed timelines.
Translational Model Systems
Our validated translational model systems enable robust assessment of novel therapeutic approaches across neurodegenerative, movement and cognitive disorders, including Parkinson’s disease and drug-induced dyskinesia.
In Vivo and Ex Vivo
Our specialised in vivo and ex vivo services facilitate the preclinical development of novel therapies for neurological and psychiatric disorders, from efficacy assessment to biomarker and post-mortem analyses.
Intellectual Property
Our intellectual property portfolio covers novel chemical entities and therapeutic targets for movement disorders, supporting their further development through strategic scientific alliances, collaborative research programmes and industry partnerships.
Preclinical Experience
Our extensive experience in preclinical neuroscience enables our scientists to provide expert guidance on study design and conduct tailored studies to rigorous scientific standards, following established SOPs and agreed timelines.
Translational Model Systems
Our validated translational model systems enable robust assessment of novel therapeutic approaches across neurodegenerative, movement and cognitive disorders, including Parkinson’s disease and drug-induced dyskinesia.
In Vivo and Ex Vivo
Our specialised in vivo and ex vivo services facilitate the preclinical development of novel therapies for neurological and psychiatric disorders, from efficacy assessment to biomarker and post-mortem analyses.
Intellectual Property
Our intellectual property portfolio covers novel chemical entities and therapeutic targets for movement disorders, supporting their further development through strategic scientific alliances, collaborative research programmes and industry partnerships.
Our team
Scientific Experts
Motac’s in-house scientists are internationally recognised experts in neuroanatomy, neurophysiology, neuropharmacology and neuropsychology, with extensive expertise in Parkinson’s and Alzheimer’s diseases, dyskinesia, movement and cognition disorders.
Widely published in peer-reviewed scientific literature, our scientists have contributed to fundamental discoveries in CNS research, from elucidating the neural mechanisms underlying Parkinson’s disease and dyskinesia to developing novel rodent and non-human primate models and identifying new therapeutic targets.
Our scientific expertise is combined with the responsiveness and efficiency required to deliver high-quality preclinical studies.
- Scientific Leadership: Internationally recognised scientists with extensive publication records and membership of research funding bodies and scientific journal editorial boards.
- Translational Expertise: Deep scientific understanding of CNS pathologies combined with the development of the industry's best available translational rodent and non-human primate models.
- Quality and Reliability: Rigorous study design and execution, with a strong emphasis on scientific quality, data integrity and adherence to agreed timelines.
Hundreds
of scientific publications
Over 700
successful stereotaxic surgeries in NHPs
Numerous
contract research studies delivered to clients worldwide
Hundreds
of scientific publications
Over 700
successful stereotaxic surgeries in NHPs
Numerous
contract research studies delivered to clients worldwide
Hundreds
of scientific publications
Over 700
successful stereotaxic surgeries in NHPs
Numerous
contract research studies delivered to clients worldwide
Our services
Fields of Research
01.
Models of movement disorders and neurodegeneration
Translational rodent and non-human primate models support the evaluation of disease mechanisms and therapeutic candidates across Parkinson’s disease and other neurodegenerative disorders.
02.
Measurement of cognitive performance
A range of behavioural and cognitive tasks is used to assess learning, memory, attention and executive function, providing robust measures of therapeutic effects in rodents and non-human primates.
03.
Integrated models of motor and cognitive function
Integrated behavioural assessments combining motor and cognitive endpoints to characterise complex neurological phenotypes and evaluate therapeutic effects across multiple functional domains.
04.
Generic techniques
We provide specialised procedures including compound administration, biological sampling, stereotaxic delivery and tissue collection, tailored to each study design and research objective.
01.
Models of movement disorders and neurodegeneration
Translational rodent and non-human primate models support the evaluation of disease mechanisms and therapeutic candidates across Parkinson’s disease and other neurodegenerative disorders.
02.
Measurement of cognitive performance
A range of behavioural and cognitive tasks is used to assess learning, memory, attention and executive function, providing robust measures of therapeutic effects in rodents and non-human primates.
03.
Integrated models of motor and cognitive function
Integrated behavioural assessments combining motor and cognitive endpoints to characterise complex neurological phenotypes and evaluate therapeutic effects across multiple functional domains.
04.
Generic techniques
We provide specialised procedures including compound administration, biological sampling, stereotaxic delivery and tissue collection, tailored to each study design and research objective.
05.
Metabolic Disorders, Ocular Diseases and Osteoporosis
Through our specialised partners, clients can access preclinical models of metabolic disorders, ocular diseases and osteoporosis, supported by tailored study designs and relevant outcome measures.
06.
In Vivo Calcium Imaging for Assessing Neural Network Activity
Real-time in vivo calcium imaging captures neural network activity in freely behaving animals, connecting cellular dynamics with behavioural responses and treatment effects.
07.
Measuring Biomarkers
Ultra-sensitive biomarker quantification in biological fluids and tissues supports the assessment of target engagement, pharmacodynamic responses and disease progression across preclinical studies.
05.
Metabolic Disorders, Ocular Diseases and Osteoporosis
Through our specialised partners, clients can access preclinical models of metabolic disorders, ocular diseases and osteoporosis, supported by tailored study designs and relevant outcome measures.
06.
In Vivo Calcium Imaging for Assessing Neural Network Activity
Real-time in vivo calcium imaging captures neural network activity in freely behaving animals, connecting cellular dynamics with behavioural responses and treatment effects.
07.
Measuring Biomarkers
Ultra-sensitive biomarker quantification in biological fluids and tissues supports the assessment of target engagement, pharmacodynamic responses and disease progression across preclinical studies.
Collaborations
Motac participates in national and international research collaborations and consortia, bringing together academic institutions, biotechnology and pharmaceutical companies, and specialised research organisations. By combining complementary expertise and translational models, these programmes help advance innovative therapeutics for complex CNS disorders.
Partners
Motac works with selected scientific, academic and preclinical partners to extend its expertise, technologies and specialised capabilities. These partnerships provide integrated, tailor-made solutions to advance innovative therapeutics through the different stages of preclinical development for CNS disorders.
Advance your preclinical programme
Discuss your next preclinical study with our scientific team and accelerate its progression towards proof of concept.
